A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Abstract

Disclosed are a composition for preventing or treating diabetes, diabesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

1 . A composition for preventing or treating diabetes, diabesity or diabetic complications, the composition comprising an oxyntomodulin analog as an active ingredient. 
     
     
         2 . The composition of  claim 1 , wherein the oxyntomodulin analog has an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NOS: 2 to 34. 
     
     
         3 . The composition of  claim 1 , wherein the oxyntomodulin analog is in the form of a conjugate with one selected from the group consisting of an immunoglobulin fragment, an antibody, elastin, albumin and fibronectin. 
     
     
         4 . The composition of  claim 3 , wherein the conjugate is a conjugate in which the oxyntomodulin analog having the amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOS: 2 to 34 is linked to an immunoglobulin Fc region through a non-peptidyl polymer. 
     
     
         5 . The composition of  claim 4 , wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, an ethylene glycol/propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, PLA (polylactic acid), PLGA (polylactic-glycolic acid), lipid polymers, chitins, hyaluronic acid, and combinations thereof. 
     
     
         6 . The composition of  claim 4 , wherein each end of the non-peptidyl polymer is linked to the immunoglobulin Fc region and the amine group or thiol group of the oxyntomodulin, respectively. 
     
     
         7 . The composition of  claim 1 , further comprising a pharmaceutical agent showing preventive or therapeutic effects against diabetes, diabesity or diabetic complications. 
     
     
         8 . The composition of  claim 1 , wherein the diabetes is insulin-dependent type 1 diabetes or insulin-independent type 2 diabetes. 
     
     
         9 . The composition of  claim 1 , wherein the diabesity results from obesity. 
     
     
         10 . A method for treating diabetes, diabesity or diabetic complications, the method comprising administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject.